With the exception of sPD-1, autologous DC vaccines are combined with (i) systemic mABs targeting PD-1 or PD-L1, (ii) platinum-based chemotherapeutics, and (iii) in situ PD-L RNAi to treat patients with both hematological cancers [multiple myeloma, acute myeloid leukemia (AML)] and solid tumors (renal cell carcinoma, mesothelioma, lymphoma, colon cancer, melanoma, ovarian cancer, pancreatic cancer, nasopharyngeal cancer, and glioblastoma). Here, HOXD13 is linked to acute myeloid leukemia.